



Full paper/Mémoire

A regioselective 1,3-dipolar cycloaddition for the synthesis of novel spiro-chromene thiadiazole derivatives

Imen Zghab^a, Belsem Trimeche^a, David Touboul^b, Hichem Ben Jannet^{a,*}^a Laboratoire de chimie hétérocyclique, produits naturels et réactivité (LR11ES39), Équipe Chimie bioorganique et produits naturels, faculté des sciences de Monastir, université de Monastir, 5000 Monastir, Tunisia^b Centre de recherche de Gif, Institut de chimie des substances naturelles, CNRS, avenue de la Terrasse, 91198 Gif-sur-Yvette cedex, France

ARTICLE INFO

Article history:

Received 29 March 2013

Accepted after revision 6 August 2013

Available online 7 October 2013

Keywords:

1,3-Dipolar cycloaddition

Diarylnitrilimines

Regioselective

Spiro cycloadduct thiadiazoles

ABSTRACT

A variety of 4'-(4-R-phenyl)-4-(methylthio)-2'-phenyl-2'H-spiro[chromene-2,5'-[1,2,3]thiadiazole] **5a–d** and 5'-(4-R-phenyl)-4-(methylthio)-3'-phenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] **6a–d** were synthesized regioselectively through the reaction of 4-(methylthio)-2H-chromene-2-thione **2** with diarylnitrilimines under refluxing dry chloroform. Whilst the reaction of 4-(allylthio)-2H-chromene-2-thione **3** with diarylnitrilimines under similar reaction conditions afforded the corresponding 4-(allylthio)-5'-(4-R-phenyl)-3'-phenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] **7a–d** and 5-(4-R-phenyl)-2'-methyl-3-phenyl-2',3'-dihydro-3H-spiro[[1,3,4]thiadiazole-2,4'-thieno[3,2-c]chromene] **9a–d** as two unisolable diastereoisomeric forms. The structures of the obtained spiro cycloadduct thiadiazoles have been assigned by means of spectroscopic measurements.

© 2013 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.

1. Introduction

The resistance towards available drugs is rapidly becoming a major worldwide problem. The need to design new compounds to deal with this resistance has become one of the most important areas of research today. Thiadiazoles have been of great interest as antitumor compounds for several scores of years [1–3]. Recent literature shows that 1,3,4-thiadiazole derivatives have received considerable attention due to their synthesis and biological importance. They exhibit a wide spectrum of interesting pharmacological properties, such as anticonvulsant [4], antituberculosis [5], analgesic [6], and leishmanicidal [7] activities, in addition to cytotoxic effects (on human non-small cell lung cancer A549) [8] as well as potent and selective PDE7 inhibitors [9]. Moreover, compounds bearing the 1,2,3-thiadiazole ring system have been reported to show antifungal [10], antitumor [11],

antihistaminic [12], insecticidal [13], and antithrombotic activity [14]. The fused chromene-2-thione derivatives show various biological properties, including anticoagulant [15], anti-inflammatory and HIV-1[16] activities.

1,3-Dipolar cycloaddition is one of the most useful reactions for the synthesis of five-membered ring heterocycles [17,18], due to a high degree of site-, regio- and stereoselectivity. Furthermore, these reactions have attracted the attention of chemists from the standpoint of reaction mechanisms. Nitrilimines are known to be among the active dipoles in 1,3-dipolar reactions, and have been extensively investigated from the viewpoint of synthetic utility and of elucidation of the reaction mechanism of 1,3-dipolar reactions [19,20].

The present work is prompted by the previously well-established results, describing the regioselective behavior of aromatic nitrilimines with thione-containing compounds. In this context, we investigated the alkylation of 4-mercapto-2H-chromene-2-thione **1**, as this was expected to provide dipolarophiles **2** and **3** with better yields and was successfully used as suitable starting materials for implementing this goal. The cycloaddition of

* Corresponding author.

E-mail address: hichem.benjannet@yahoo.fr (H.B. Jannet).

diarylnitrilimines to the C=S double bond compound **2** was strictly regioselective and afforded a mixture of both regioisomer of new spiro cycloadduct thiadiazoles **5a–d** and **6a–d**. In similar reaction conditions, 4-(allylthio)-2*H*-chromene-2-thione **3** proceeded with exclusive site selectivity, via 1,3-dipolar cycloaddition, and afforded only the major regioisomers of the mixture spirochromene[1,3,4]thiadiazoles **7a–d** and **9a–d**.

2. Results and discussion

Our first key intermediate was the 4-(methylthio)-2*H*-chromene-2-thione **2**, which was obtained in good yield (70%) by stirring a mixture of 4-mercapto-2*H*-chromene-2-thione **1** and (5 equiv) *N,N*-dimethylformamide dimethyl acetal (DMFDMA) [21] during 3 h in dry toluene (Scheme 1). The mass spectrum, recorded in ESI–HRMS, showed for product **2** the molecular ion peak [M+H]⁺ at *m/z* 209.0096, which is consistent with the molecular formula of C₁₀H₉OS₂, as well as the ¹H NMR spectrum showed a singlet at 2.56 ppm, corresponding to the methyl group.

Likewise, we have studied the behavior of derivative **1** with an excess of allyl bromide [22] in the presence of potassium carbonate under refluxing dry CHCl₃; the *S*-alkylation process took place and gave the 4-(allylthio)-2*H*-chromene-2-thione **3** (Scheme 1). Compatible ESI–HRMS and spectral measurements for this compound were gained (See Experimental section).

A survey of the literature revealed a lack of information related to the synthesis of two regioisomer spirothiadiazoles via the 1,3-dipolar cycloaddition reaction. Most of the work that we have found described the condensation of dipolarophile (C=S) with an equivalent amount of a diarylnitrilimine as a route to the only spiro cycloadduct [23–25].

Thus, prompted by these findings, we studied the condensation of the 4-(methylthio)-2*H*-chromene-2-thione **2**, under refluxing dry chloroform, with a stoichiometric amount of diarylnitrilimines (generated in situ via triethylamine dehydrohalogenation of the corresponding hydrazoneyl chlorides **4a–d**) [26], completed in 24 h as shown by TLC, and afforded, in each case, two regioisomer products (Scheme 2). The structure of the isolated products were established to be 4'-(4-*R*-phenyl)-4-(methylthio)-2'-phenyl-2'*H*-spiro[chromene-2,5'-[1,2,3]thiadiazole] **5a–d** and 5'-(4-*R*-phenyl)-4-(methylthio)-3'-phenyl-3'*H*-spiro[chromene-2,2'-[1,3,4]thiadiazole] **6a–d** based on the spectroscopic measurements (¹H, ¹³C NMR, 2D and ESI–HRMS).

The comparison of the spectral data of the cycloadducts **5c** and **6c** shows that the two compounds have the same


spirothiadiazoles skeleton. Indeed, the mass spectra recorded in ES⁺ mode are identical and showed for both compounds the molecular ion peaks [M+H]⁺ at *m/z* 448.1. Moreover, the assignment of regiochemistry to **5c** and **6c** cannot be differentiated by analysis of standard ¹H and ¹³C NMR spectra. For this reason, the only difference in cyclization between the two compounds occurred at the C-2 spiro center, as judged by the NOESY experiments, by the observation of a dipolar interaction between the ethylenic proton H-3 and aromatic protons fixed at the nitrogen, which confirms the structure of the cycloadduct **6c**.

On the other hand, the ¹³C NMR, reinforced by HMBC for derivative **6c**, indicates the presence of characteristic signals based on their chemical shifts, readily assigned the new spiro center C-2 and the iminic carbon C-5' at δ_C 112.5 and at 138.6 ppm, respectively. Additional supports for our assignments were provided by a HMBC experiment that revealed significant correlations between the aromatic protons H-2'',6'' with carbons C-5' (138.6 ppm) and C-4'' (146,7 ppm). The same spectrum showed the correlation of the ethylenic proton H-3 with both quaternary carbons C-2 and C-4a at 138.6 ppm and at 118,6 ppm, respectively.



On the other hand, the comparison of the ¹³C NMR data of the spiro cycloadduct **5c** to those of **6c** suggest that this compound did not have the same regiochemistry, showing the new generated spirocyclic quaternary carbon C-2 at δ_C 100.9 ppm and the iminic carbon C-4' at δ_C 149.0 ppm. However, the relative deshielding of the iminic carbon (C-4' δ_C 149.0 ppm) in cycloadduct **5c**, due to the absence of the sulfur atom, reinforces the proposed structure. The reaction is thus regioselective.


Analogously, 4-(allylthio)-2*H*-chromene-2-thione **3** reacted with a series of diarylnitrilimines **4a–d** [26] under the same previously described reaction conditions, and gave two types of spiroheterocycles, **7a–d** and **9a–d**. For example, the two spiroheterocycles **7c** and **9c** were obtained in the amount of the product ratio 14:75. Once again, the spiroheterocycles **7c** and **9c** were obtained preferentially. Indeed, the 1,3-dipolar cycloaddition reaction did not afford the corresponding regioisomer cycloadducts **8c** and **10c**, which could be formed as minors; it was difficult to isolate them quantitatively (Scheme 3).

The structures of cycloadducts **7a–d** and **9a–d** were confirmed on the basis of their spectroscopic data (ES–MS, ¹H, and ¹³C NMR). Indeed, the mass spectrum recorded in ES⁺ mode showed for both products **7c** and **9c** molecular ion peaks [M+H]⁺ at *m/z* = 474.1. Furthermore, the structural assignment of the products **7c** and **9c** was made on the basis of ¹H and ¹³C NMR spectral analysis and by comparison of their spectroscopic data with those reported



Scheme 1. S-Alkylation of 4-mercapto-2*H*-chromene-2-thione **1**.

Scheme 2. Synthesis of spiro-chromene[1,2,3]thiadiazole **5a-d** and spiro-chromene[1,3,4]thiadiazole **6a-d**.Scheme 3. Synthesis of spiro-chromene[1,3,4]thiadiazoles **7a-d** and **9a-d**.



Scheme 4. Proposed mechanism for the synthesis of 2-methyl-2H-thieno[3,2-c]chromene-4(3H)-thione **13**.

for related systems. In particular, ¹H NMR analysis clearly indicated that the cycloadduct **7c** maintains the allylic system. In addition, the ¹³C NMR spectrum showed two signals at δ_C 113.3 and 139.6 ppm, attributable to the spirocarbon C-2 and to the iminic carbon C-5', respectively. This value located the spiro center near the electronegative nitrogen atom of the thiadiazole ring.

Indeed, the ¹H NMR spectrum of **9c** revealed the two methyl groups as two doublet signals at δ_H 1.06 and 1.37, corresponding to the major (CH_{3a}, *J* = 6.6 Hz) and minor (CH_{3b}, *J* = 6.6 Hz) diastereoisomers, respectively, together with a multiplet signal at δ_H 3.81 relative to the proton H-2a,b. In addition, the major diastereoisomer H-3b exhibits two closely spaced doublet of doublets (δ_H 2.76 *J* = 15.6 Hz, *J* = 6.9 Hz and δ_H 2.83 *J* = 16.2 Hz, *J* = 8.1 Hz), while the minor diastereoisomer H-3a exhibits two widely spaced doublet of doublets (δ_H 2.28 *J* = 16.5 Hz, *J* = 3.6 Hz and δ_H 3.21 *J* = 16.5 Hz, *J* = 8.7 Hz). The same spectrum showed two doublets at δ_H 7.98 (*J* = 8.1 Hz, H-2'',6'') and 8.17 (*J* = 8.1 Hz, H-3'',5'') in addition to the multiplet for the aromatic protons at δ_H 6.91–7.39 ppm.

The ¹³C NMR spectrum of **9c** was also a good support for the proposed structure, since it exhibited characteristic signals at δ_C 22.5; 23.5, 44.0; 44.3 and 44.4 ppm, corresponding to the carbons of the methyl groups, to C-3_{a,b} and C-2_{a,b} of the 2-methyl-2,3-dihydrothiophene moiety, respectively. Furthermore, the comparison of the ¹³C NMR data of spirothiadiazole **9c** with those of compound **7c** confirmed that compound **9c** shows the same regiochemistry, with the spiro carbon C-4 appearing at δ_C 113.8 ppm. Moreover, the regiochemistry was also confirmed by the NOE observed between the protons CH_{3a,b} and H-2_{a,b} and the aromatic protons fixed at the nitrogen.

With the aim of understanding if compounds **9a–d** were obtained starting from compounds **7a–d** or directly

starting from the rearranged compound **13** formed as explained in Scheme 4 [27,28], we subjected compound **3** under reflux of chloroform in the absence of the diarylnitrilimines, and we also applied the same conditions to compound **7c**. This allowed us to conclude that cycloadducts **9a–d** could be obtained at the same time from the reaction of cycloaddition on the rearranged 2-methyl-2H-thieno[3,2-c]chromene-4(3H)-thione **13** and from the rearrangement of compounds **7a–d**.

3. Conclusion

In this paper, we described the two-step synthesis of an interesting rigid heterosystem with a strategy that allows the development of a new series of novel spiro-chromene thiadiazole derivatives in a fast way through the cycloadditions of diarylnitrilimines to the C=S double bond. The fusion of two biologically relevant systems as they are, the thiadiazole ring along with the S-alkyl chromene-2-thione system spirojoined, may make them excellent compounds for bioactivity trials.

4. Experimental

Melting points were taken on a Büchi-510 capillary melting point apparatus. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were recorded with AC-300 Bruker spectrometers. HRMS spectra were acquired with an ESI-TOF (LCT Premier XE, Waters) using the reflectron mode in the positive ion mode. Leucine-enkephaline peptide was employed as the LockSpray lockmass. Commercial TLC plates (Silica gel 60, F254, SDS) were used to monitor the progress of the reaction. Column chromatography analysis was performed with silica gel 60 (particle size 40–63 μm, SDS).

4.1. General procedure for the reaction of the 4-mercapto-2H-chromene-2-thione **1** with DMFDMA

To a stirred suspension of compound **1** (1 g, 1 mol) in dry toluene (70 mL), an excess of *N,N*-dimethylformamide dimethylacetal (12 mL, 5 equiv.) was added. The mixture was heated at 100 °C for almost 3 h. After the removal of the volatile components in vacuo, the purification of the obtained brownish oily residue on silica gel (ether petroleum/ethyl acetate as 7:3 v/v) afforded **2** as an orange powder.

4.1.1. 4-(Methylthio)-2H-chromene-2-thione (**2**)

Orange powder, yield 70%, mp 179 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.56 (s, 3H, CH₃), 7.06 (s, 1H, H-3), 7.32 (t, 1H, *J* = 8.1 Hz, H-6), 7.47 (m, 1H, H-8), 7.59 (t, 1H, *J* = 8.4 Hz, H-7), 7.79 (d, 1H, *J* = 8.1 Hz, H-5). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.0 (CH₃), 117.2 (C-3), 119.3 (C-8), 120.6 (C-7), 123.6 (C-5), 125.2 (C-4a), 132.6 (C-6), 151.5 (C-8a), 154.3 (C-4), 194.2 (C-2). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₁₀H₉OS₂)⁺: 209.0095; found: 209.0096.

4.2. Reaction of compound **1** with allylic halide

An excess of allyl bromide was added to a solution of compound **1** (0.5 g, 0.25 mmol) and 0.11 mmol of anhydrous potassium carbonate in dry CHCl₃ (30 mL). The mixture was refluxed for 24 h. The residue obtained after removing the solvent in vacuo was chromatographed on silica gel, employing ether petroleum/dichloromethane; 1:1, as an eluent. Crystallization from (CH₂Cl₂/EP, 2:8) gives orange cottony **3**.

4.2.1. 4-(Allylthio)-2H-chromene-2-thione (**3**)

Orange cottony, yield 64%, mp 131 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 3.75 (d, 2H, *J* = 7.5 Hz, CH₂), 5.37 (dd, 1H, *J* = 12.0 Hz, *J* = 1.2 Hz, –CH=CH_{2(a)}), 5.48 (dd, 1H, *J* = 16.8 Hz, *J* = 1.2 Hz, –CH=CH_{2(b)}), 5.95 (m, 1H, –CH₂–CH=), 7.12 (s, 1H, H-3), 7.33 (m, 1H, H-6), 7.46 (dd, 1H, *J* = 8.4 Hz, *J* = 1.2 Hz, H-8), 7.60 (m, 1H, H-7), 7.76 (dd, 1H, *J* = 8.1 Hz, *J* = 1.5 Hz, H-5). ¹³C NMR (75 MHz, CDCl₃): δ_C 34.1 (CH₂), 117.5 (C-3), 119.8 (C-4a), 120.7 (C-8), 121.8 (–CH=CH₂), 124.0 (C-6), 125.5 (C-5), 130.3 (–CH₂–CH=), 132.9 (C-7), 150.1 (C-4), 154.9 (C-8a), 194.4 (C-2). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₁₂H₁₁OS₂)⁺: 235.0251; found: 235.0242.

4.3. Synthesis of compounds **5a–d** and **6a–d** (general procedure)

A mixture of **2** (1 mmol) and the appropriate hydrazoneoyl chloride **4a–d** (1 mmol) in anhydrous CHCl₃ (20 mL) containing triethylamine (1 mmol) was boiled under reflux for 24 h. The formed triethylamine hydrochloride was separated by filtration and the clear reaction mixture was evaporated till dryness under reduced pressure. After completion of the reaction, the resulting crude brownish oil was chromatographed on silica gel and eluted with (ether petroleum/dichloromethane; 1:1). This allowed the separation of compounds **5a–d** and **6a–d**.

4.3.1. 4-(Methylthio)-2',4'-diphenyl-2'H-spiro[chromene-2,5'-[1,2,3]thiadiazole] (**5a**)

Orange solid, yield 15%, mp 103 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.35 (s, 3H, CH₃), 5.23 (s, 1H, H-3), 6.89–7.13 (m, 5H, H-2''',4''',6''',6,8), 7.32–7.63 (m, 7H, H-3'',3''',4'',5'',5''',5,7), 7.94 (d, 2H, *J* = 8.1 Hz, H-2'',6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.4 (CH₃), 101.0 (C-3), 101.0 (C-2), 116.0 (C-6), 117.6 (C-4'''), 122.0 (C-4a), 123.5 (C-2''',6'''), 124.8 (C-8), 126.1 (C-3''',5'''), 128.2 (C-2'',6''), 128.2 (C-3'',5''), 128.6 (C-5), 129.5 (C-7), 137.2 (C-4), 142.0 (C-1''), 146.7 (C-1'''), 148.0 (C-4''), 149.0 (C-4'), 150.0 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₃H₁₉N₂O₂S₂)⁺: 403.0939; found: 403.0937.

4.3.2. 4'-(4-Chlorophenyl)-4-(methylthio)-2'-phenyl-2'H-spiro[chromene-2,5'-[1,2,3]thiadiazole] (**5b**)

Pale yellow solid, yield 16%, mp 115 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.35 (s, 3H, CH₃), 5.23 (s, 1H, H-3), 6.89–7.13 (m, 5H, H-2''',4''',6''',6,8), 7.32–7.63 (m, 6H, H-2'',3''',5''',5,6'',7), 7.94 (d, 2H, *J* = 8.1 Hz, H-3'',5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.4 (CH₃), 101.8 (C-3), 101.8 (C-2), 116.0 (C-6), 117.6 (C-4'''), 120.0 (C-4a), 123.5 (C-2''',3''',5''',6'''), 124.8 (C-8), 126.1 (C-3''',5'''), 128.2 (C-2'',6''), 128.6 (C-5), 130.0 (C-7), 137.2 (C-4), 142.0 (C-1''), 147.0 (C-1'''), 148.0 (C-4''), 149.0 (C-4'), 150.0 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₃H₁₈N₂O₂Cl)⁺: 437.0549; found: 437.0553.

4.3.3. 4-(Methylthio)-4'-(4-nitrophenyl)-2'-phenyl-2'H-spiro[chromene-2,5'-[1,2,3]thiadiazole] (**5c**)

Orange solid, yield 18%, mp 144 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.39 (s, 3H, CH₃), 5.57 (s, 1H, H-3), 6.95 (m, 1H, H-6), 7.09–7.20 (m, 6H, H-2''',3''',4''',5''',6''',8), 7.35 (m, 1H, H-7), 7.81 (m, 3H, H-2'',5,6''), 8.27 (d, 2H, *J* = 8.1 Hz, H-3'',5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 13.9 (CH₃), 100.9 (C-3), 100.9 (C-2), 116.0 (C-6), 117.6 (C-4'''), 122.0 (C-4a), 123.5 (C-2''',3''',5''',6'''), 124.8 (C-8), 126.1 (C-3''',5'''), 128.2 (C-2'',6''), 128.6 (C-5), 130.0 (C-7), 137.2 (C-4), 142.0 (C-1''), 147.0 (C-1'''), 148.0 (C-4''), 149.0 (C-4'), 150.0 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₃H₁₈N₃O₃S₂)⁺: 448.0790; found: 448.0794.

4.3.4. 4-(Methylthio)-2'-phenyl-4'-(*p*-tolyl)-2'H-spiro[chromene-2,5'-[1,2,3]thiadiazole] (**5d**)

Yellow solid, yield 20%, mp 166 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.35 (s, 3H, CH₃), 2.80 (s, 3H, CH₃-Ph), 5.23 (s, 1H, H-3), 6.89–7.13 (m, 5H, H-2''',4''',6''',6,8), 7.32–7.63 (m, 6H, H-3'',3''',5''',5,5''',5,7), 7.94 (d, 2H, *J* = 8.1 Hz, H-2'',6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.4 (CH₃), 21.3 (CH₃-Ph), 100.8 (C-3), 100.8 (C-2), 116.0 (C-6), 117.6 (C-4'''), 122.0 (C-4a), 124.8 (C-8), 126.1 (C-3''',5'''), 128.2 (C-2''',3''',5''',6'''), 128.2 (C-2'',6''), 128.6 (C-5), 130.0 (C-7), 137.2 (C-4), 142.0 (C-1''), 147.0 (C-1'''), 148.0 (C-4''), 149.0 (C-4'), 150.0 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₄H₂₁N₂O₂S₂)⁺: 417.1017; found: 417.1022.

4.3.5. 4-(Methylthio)-3',5'-diphenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (**6a**)

Orange solid, yield 78.5%, mp 177 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.39 (s, 3H, CH₃), 5.76 (s, 1H,

H-3), 6.99 (d, 1H, *J* = 8.1 Hz, H-6), 7.10 (m, 2H, H-5''',8), 7.32 (m, 3H, H-3''',6''',7), 7.41 (m, 2H, H-2''',7'''), 7.56 (m, 4H, H-3''',4''',5''',5), 7.73 (m, 2H, H-2'',6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.0 (CH₃), 112.6 (C-3), 112.6 (C-2), 117.9 (C-6), 118.8 (C-2''',7'''), 119.8 (C-4a), 122.6; 122.7 (C-8, 5'''), 123.9 (C-5), 126.5 (C-3'',5''), 128.6 (C-2'',6''), 128.7 (C-3''',6'''), 129.5 (C-7), 130.8 (C-1''), 131.3 (C-4''), 137.1 (C-4), 142.1 (C-5'), 142.2 (C-1'''), 149.7 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₃H₁₉N₂OS₂)⁺: 403.0939; found: 403.0949.

4.3.6. 5'-(4-Chlorophenyl)-4-(methylthio)-3'-phenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (6b)

Pale yellow solid, yield 80.5%, mp 192 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.38 (s, 3H, CH₃), 5.73 (s, 1H, H-3), 6.98 (d, 1H, *J* = 8.1 Hz, H-6), 7.10 (m, 2H, H-5''',8), 7.33 (m, 3H, H-3''',6''',7), 7.38 (d, 2H, *J* = 8.1 Hz, H-2'',6''), 7.54 (m, 3H, H-2''',5,7'''), 7.61 (d, 2H, *J* = 8.1 Hz, H-3''',5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.0 (CH₃), 112.3 (C-3), 113.0 (C-2), 117.9 (C-6), 118.8 (C-8,5'''), 119.7 (C-4a), 122.7 (C-2''',7'''), 123.0 (C-5), 127.6 (C-3'',5''), 128.7 (C-2'',6''), 128.8 (C-3''',6'''), 129.9 (C-1''), 130.1 (C-7), 135.3 (C-4''), 137.4 (C-4), 141.0 (C-5'), 141.9 (C-1'''), 149.5 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₃H₁₈N₂O₂Cl)⁺: 437.0549; found: 437.0538.

4.3.7. 4-(Methylthio)-5'-(4-nitrophenyl)-3'-phenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (6c)

Orange solid, yield 92%, mp 208 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.29 (s, 3H, CH₃), 6.87 (s, 1H, H-3), 6.90 (d, 1H, *J* = 8.1 Hz, H-6), 7.03 (m, 2H, H-5''',8), 7.22 (m, 1H, H-7), 7.24 (m, 2H, H-3''',6'''), 7.46 (m, 3H, H-2''',5,7'''), 7.73 (d, 2H, *J* = 8.1 Hz, H-2'', 6''), 8.16 (d, 2H, *J* = 8.1 Hz, H-3'', 5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 13.0 (CH₃), 110.8 (C-3), 112.5 (C-2), 116.8 (C-6), 118.1 (C-2''',7'''), 118.6 (C-4a), 122.4; 122.6 (C-8, 5'''), 122.9 (C-3'',5''), 122.9 (C-5), 125.8 (C-2'',6''), 127.7 (C-3''',6'''), 130.0 (C-7), 136.5 (C-1''), 136.8 (C-4), 138.6 (C-5'), 140.4 (C-1'''), 146.7 (C-4''), 148.1 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₃H₁₈N₃O₃S₂)⁺: 448.0790; found: 448.0789.

4.3.8. 4-(Methylthio)-3'-phenyl-5'-(p-tolyl)-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (6d)

Yellow solid, yield 85%, mp 170 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 2.38 (s, 3H, CH₃), 2.80 (s, 3H, CH₃-Ph), 5.73 (s, 1H, H-3), 6.98 (d, 1H, *J* = 8.1 Hz, H-6), 7.10 (m, 2H, H-5''',8), 7.33–7.54 (m, 8H, H-2''',3''',3''',5''',5,6''',7,7'''), 7.61 (d, 2H, *J* = 8.1 Hz, H-2'',6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 14.0 (CH₃), 21.3 (CH₃-Ph), 112.3 (C-3), 113.0 (C-2), 117.9 (C-6), 118.8 (C-8,5'''), 119.7 (C-4a), 122.7 (C-2''',7'''), 123.0 (C-5), 127.6 (C-3'',5''), 127.6 (C-2'',6''), 128.8 (C-3''',6'''), 129.9 (C-1''), 130.1 (C-7), 135.3 (C-4''), 137.4 (C-4), 141.0 (C-5'), 141.9 (C-1'''), 149.5 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₄H₂₁N₂O₂S₂)⁺: 417.1017; found: 417.1022.

4.4. Preparation of compounds 7a–d and 9a–d (general procedure)

A mixture of **2** (1 mmol) and the appropriate hydrazono-noyl chloride **4a–d** (1 mmol) in anhydrous CHCl₃ (20 mL)

was added at room temperature to 1 equiv of triethylamine. The reaction medium was heated to 75 °C and kept under reflux for 24 h (TLC). The inorganic salts were filtered off; the filtrate was evaporated in vacuo. Chromatography of the brownish oily residue on silica gel eluting with (ether petroleum/dichloromethane; 1:1) allowed the separation of compounds **7a–d** and **9a–d**.

4.4.1. 4-(Allylthio)-3',5'-diphenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (7a)

Orange powder, yield 12%, mp 160 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 3.53 (m, 2H, CH₂), 5.14 (dd, 1H, *J* = 10.0 Hz, *J* = 1.2 Hz, –CH=CH_{2(a)}), 5.21 (dd, 1H, *J* = 16.8 Hz, *J* = 1.2 Hz, –CH=CH_{2(b)}), 5.86 (m, 1H, –CH₂–CH=), 5.97 (s, 1H, H-3), 6.99 (m, 1H, H-6), 7.11 (m, 2H, H-4''',8), 7.28–7.35 (m, 6H, H-2''',3''',5''',5,6''',7), 7.54 (m, 3H, H-3''',4''',5''), 7.63 (m, 2H, H-2'',6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 33.8 (CH₂), 114.0 (C-2), 116.1 (C-3), 117.5 (C-8), 118.5 (C-2''',6'''), 118.5 (–CH=CH₂), 119.4 (C-4a), 122.3 (C-4'''), 122.4 (C-6), 124.0 (C-5), 127.1 (C-3'',5''), 128.2 (C-3''',5'''), 128.3 (C-2'',6''), 129.4 (C-4''), 130.3 (–CH₂–CH=), 131.7 (C-7), 134.0 (C-1''), 134.8 (C-4), 140.5 (C-5'), 141.3 (C-1'''), 149.3 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₅H₂₁N₂OS₂)⁺: 429.1095; found: 429.1105.

4.4.2. 4-(Allylthio)-5'-(4-chlorophenyl)-3'-phenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (7b)

Brown solid, yield 21%, mp 106 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 3.53 (m, 2H, CH₂), 5.14 (dd, 1H, *J* = 9.0 Hz, *J* = 0.9 Hz, –CH=CH_{2(a)}), 5.21 (dd, 1H, *J* = 16.8 Hz, *J* = 0.9 Hz, –CH=CH_{2(b)}), 5.86 (m, 1H, –CH₂–CH=), 5.97 (s, 1H, H-3), 6.99 (d, 1H, *J* = 8.1 Hz, H-6), 7.11 (m, 2H, H-4''',8), 7.28–7.37 (m, 5H, H-2''',3''',5''',6''',7), 7.54 (d, 2H, *J* = 7.8 Hz, H-3'', 5''), 7.63 (m, 3H, H-2'',5,6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 33.8 (CH₂), 112.2 (C-2), 116.1 (C-3), 117.5 (C-8), 118.5 (C-2''',6'''), 118.5 (–CH=CH₂), 119.4 (C-4a), 122.3 (C-4'''), 122.4 (C-6), 124.0 (C-5), 127.1 (C-3'',5''), 128.2 (C-3''',5'''), 128.3 (C-2'',6''), 129.4 (C-1''), 130.3 (–CH₂–CH=), 131.4 (C-7), 134.4 (C-4''), 134.8 (C-4), 140.5 (C-5'), 141.3 (C-1'''), 149.3 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₅H₂₀N₂O₂Cl)⁺: 463.0706; found: 463.0692.

4.4.3. 4-(Allylthio)-5'-(4-nitrophenyl)-3'-phenyl-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (7c)

Red solid, yield 14%, mp 109 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 3.42 (m, 2H, CH₂), 5.03 (dd, 1H, *J* = 10.2 Hz, *J* = 1.2 Hz, –CH=CH_{2(a)}), 5.12 (dd, 1H, *J* = 16.8 Hz, *J* = 1.2 Hz, –CH=CH_{2(b)}), 5.71 (m, 1H, –CH₂–CH=), 5.79 (s, 1H, H-3), 6.88 (m, 1H, H-6), 7.02 (m, 2H, H-4''',8), 7.22 (m, 1H, H-7), 7.24 (m, 2H, H-3''',5'''), 7.41 (m, 2H, H-2''',6'''), 7.51 (dd, 1H, *J* = 8.1 Hz, *J* = 1.5 Hz, H-5), 7.71 (d, 2H, *J* = 8.1 Hz, H-2'',6''), 8.14 (d, 2H, *J* = 8.1 Hz, H-3'',5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 34.3 (CH₂), 113.3 (C-2), 115.8 (C-3), 117.9 (C-8), 119.3 (–CH=CH₂), 119.7 (C-2''',6'''), 120.3 (C-4a), 123.0 (C-4'''), 123.6 (C-6), 123.9 (C-2'',6''), 124.5 (C-5), 126.8 (C-3'',5''), 128.8 (C-3''',5'''), 131.0 (C-7), 131.8 (–CH₂–CH=), 135.5 (C-1''), 137.5 (C-4), 139.6 (C-5'), 141.4 (C-1'''), 147.8 (C-4''), 149.4 (C-8a). ESI–HRMS: *m/z* [M+H]⁺ calcd for (C₂₅H₂₀N₃O₃S₂)⁺: 474.0946; found: 474.0936.

4.4.4. 4-(Allylthio)-3'-phenyl-5'-(p-tolyl)-3'H-spiro[chromene-2,2'-[1,3,4]thiadiazole] (7d)

Yellow solid, yield 19%, mp 140 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 3.42 (m, 2H, CH₂), 5.03 (dd, 1H, J = 9.0 Hz, J = 0.9 Hz, -CH=CH_{2(a)}), 5.12 (dd, 1H, J = 16.8 Hz, J = 0.9 Hz, -CH=CH_{2(b)}), 5.71 (m, 1H, -CH₂-CH=), 5.79 (s, 1H, H-3), 6.88 (m, 1H, H-6), 7.02 (m, 2H, H-4''', 8), 7.20–7.51 (m, 8H, H-2''', 3''', 5'', 5''', 5'', 6''', 7), 7.63 (d, 2H, J = 8.1 Hz, H-2'', 6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 21.3 (CH₃), 34.3 (CH₂), 114.0 (C-2), 115.8 (C-3), 117.9 (C-8), 119.3 (-CH=CH₂), 119.7 (C-2''', 6'''), 120.3 (C-4a), 123.0 (C-4'''), 123.6 (C-6), 124.5 (C-5), 126.8 (C-3'', 5''), 126.8 (C-2'', 6''), 128.8 (C-3''', 5'''), 131.0 (C-7), 131.8 (-CH₂-CH=), 135.5 (C-1''), 137.5 (C-4), 137.7 (C-4''), 139.6 (C-5'), 141.4 (C-1'''), 149.4 (C-8a). ESI-HRMS: *m/z* [M+H]⁺ calcd for (C₂₆H₂₃N₂O₂S)⁺: 443.1207; found: 443.1211.

4.4.5. 2'-Methyl-3,5-diphenyl-2',3'-dihydro-3H-spiro[[1,3,4]thiadiazole-2,4'-thieno[3,2-c]chromene] (9a)

Red crystals, yield 89%, mp 190 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 1.09 (d, 3H, J = 6.6 Hz, CH_{3a}), 1.36 (d, 3H, J = 6.6 Hz, CH_{3b}), 2.31 (dd, 1H, J = 16.5 Hz, J = 3.0 Hz, H-3a), 2.76 (dd, 1H, J = 16.2 Hz, J = 6.6 Hz, H-3b), 2.83 (dd, 1H, J = 16.5 Hz, J = 8.1 Hz, H-3b), 3.24 (dd, 1H, J = 16.5 Hz, J = 8.7 Hz, H-3a), 3.80 (m, 2H, H-2a,b), 6.82–7.21 (m, 4H, H-4''', 6, 7, 8), 7.25–7.30 (m, 5H, H-2''', 3''', 5'', 6''', 9), 7.38–7.41 (m, 3H, H-3'', 4'', 5''), 7.51 (m, 2H, H-2'', 6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 22.9 (CH_{3a}), 23.5 (CH_{3b}), 42.9 (C-3a), 43.0 (C-3b), 44.4 (C-2), 114.4 (C-4), 116.9 (C-6), 117.5 (C-4'''), 117.9 (C-2''', 6'''), 122.0 (C-3a), 122.2 (C-9a), 122.7 (C-8), 125.1 (C-9), 126.4 (C-3'', 5''), 128.6 (C-3''', 5'''), 128.6 (C-2'', 6''), 129.0 (C-4''), 129.6 (C-1''), 130.4 (C-7), 137.9; 138.1 (C-9b), 140.5; 140.7 (C-5'), 141.8; 142.0 (C-1'''), 150.2 (C-5a). ESI-HRMS: *m/z* [M+H]⁺ calcd for (C₂₅H₂₁N₂O₂S)⁺: 429.1095; found: 429.1104.

4.4.6. 5-(4-Chlorophenyl)-2'-methyl-3-phenyl-2',3'-dihydro-3H-spiro[[1,3,4]thiadiazole-2,4'-thieno[3,2-c]chromene] (9b)

Yellow crystals, yield 90%, mp 110 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 1.07 (d, 3H, J = 6.9 Hz, CH_{3a}), 1.36 (d, 3H, J = 6.9 Hz, CH_{3b}), 2.31 (dd, 1H, J = 16.5 Hz, J = 3.0 Hz, H-3a), 2.72 (dd, 1H, J = 16.2 Hz, J = 6.6 Hz, H-3b), 2.84 (dd, 1H, J = 16.5 Hz, J = 8.1 Hz, H-3b), 3.21 (dd, 1H, J = 16.5 Hz, J = 8.7 Hz, H-3a), 3.80 (m, 2H, H-2a,b), 6.88 (m, 1H, H-6), 7.01 (m, 1H, H-9), 7.06 (m, 2H, H-2''', 6'''), 7.14 (m, 1H, H-7), 7.18 (m, 2H, H-3''', 5'''), 7.33 (d, 2H, J = 8.1 Hz, H-2'', 6''), 7.42 (m, 2H, H-4''', 8), 7.57 (d, 2H, J = 8.1 Hz, H-3'', 5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 22.6 (CH_{3a}), 23.6 (CH_{3b}), 43.0 (C-3a), 44.3 (C-3b), 44.4 (C-2), 114.4 (C-4), 116.9 (C-6), 117.0 (C-4'''), 117.9 (C-2''', 6'''), 120.4 (C-3a), 120.7 (C-9a), 122.7 (C-8), 122.9 (C-1''), 125.3; 125.9 (C-9), 127.5 (C-3'', 5''), 128.8 (C-2'', 6''), 128.9 (C-3''', 5'''), 130.5 (C-7), 135.2; 135.3 (C-4''), 137.9; 138.1 (C-9b), 140.5; 140.7 (C-5'), 141.6; 141.8 (C-1'''), 150.1 (C-5a). ESI-HRMS: *m/z* [M+H]⁺ calcd for (C₂₅H₂₀N₂O₂Cl)⁺: 463.0706; found: 463.0728.

4.4.7. 2'-Methyl-5-(4-nitrophenyl)-3'-phenyl-2',3'-dihydro-3H-spiro[[1,3,4]thiadiazole-2,4'-thieno[3,2-c]chromene] (9c)

Red solid, yield 75%, mp 148 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 1.06 (d, 3H, J = 6.6 Hz, CH_{3a}),

1.37 (d, 3H, J = 6.6 Hz, CH_{3b}), 2.28 (dd, 1H, J = 16.5 Hz, J = 3.6 Hz, H-3a), 2.76 (dd, 1H, J = 15.6 Hz, J = 6.9 Hz, H-3b), 2.83 (dd, 1H, J = 16.2 Hz, J = 8.1 Hz, H-3b), 3.21 (dd, 1H, J = 16.5 Hz, J = 8.7 Hz, H-3a), 3.81 (m, 2H, H-2a,b), 6.91 (m, 1H, H-6), 7.03 (m, 1H, H-9), 7.06 (m, 2H, H-2''', 6'''), 7.18 (m, 1H, H-7), 7.24 (m, 2H, H-3''', 5'''), 7.39 (m, 2H, H-4''', 8), 7.98 (d, 2H, J = 8.1 Hz, H-2'', 6''), 8.17 (d, 2H, J = 8.1 Hz, H-3'', 5''). ¹³C NMR (75 MHz, CDCl₃): δ_C 22.5 (CH_{3a}), 23.5 (CH_{3b}), 44.0 (C-3a), 44.3 (C-3b), 44.4 (C-2), 113.8 (C-4), 116.9 (C-6), 117.9 (C-4'''), 118.4 (C-2''', 6'''), 119.7 (C-3a), 120.2 (C-9a), 122.9 (C-8), 123.9 (C-3'', 5''), 125.3; 125.4 (C-9), 126.8 (C-2'', 6''), 128.9; 129.0 (C-3''', 5'''), 130.7 (C-7), 137.5; 137.6 (C-1''), 138.6; 138.7 (C-9b), 139.2; 139.3 (C-5'), 141.2; 141.4 (C-1'''), 147.8 (C-4''), 149.8 (C-5a). ESI-HRMS: *m/z* [M+H]⁺ calcd for (C₂₅H₂₀N₃O₃S₂)⁺: 474.0946; found: 474.0934.

4.4.8. 2'-Methyl-3-phenyl-5-(p-tolyl)-2',3'-dihydro-3H-spiro[[1,3,4]thiadiazole-2,4'-thieno[3,2-c]chromene] (9d)

Yellow solid, yield 70%, mp 156 °C (CH₂Cl₂/EP, 2:8). ¹H NMR (300 MHz, CDCl₃): δ_H 1.07 (d, 3H, J = 6.6 Hz, CH_{3a}), 1.36 (d, 3H, J = 6.6 Hz, CH_{3b}), 2.34 (s, 3H, CH₃), 2.31 (dd, 1H, J = 16.5 Hz, J = 3.6 Hz, H-3a), 2.71 (dd, 1H, J = 15.6 Hz, J = 6.9 Hz, H-3b), 2.84 (dd, 1H, J = 16.2 Hz, J = 8.1 Hz, H-3b), 3.21 (dd, 1H, J = 16.5 Hz, J = 8.7 Hz, H-3a), 3.80 (m, 2H, H-2a,b), 6.88 (m, 1H, H-6), 7.01 (m, 1H, H-9), 7.06 (m, 2H, H-2''', 6'''), 7.14 (m, 1H, H-7), 7.18 (m, 2H, H-3''', 5'''), 7.39 (m, 2H, H-4''', 8), 7.30 (d, 2H, J = 8.1 Hz, H-3'', 5''), 7.85 (d, 2H, J = 8.1 Hz, H-2'', 6''). ¹³C NMR (75 MHz, CDCl₃): δ_C 21.3 (CH₃), 22.6 (CH_{3a}), 23.6 (CH_{3b}), 43.0 (C-3a), 44.3 (C-3b), 44.4 (C-2), 114.4 (C-4), 116.9 (C-6), 117.0 (C-4'''), 117.9 (C-2''', 6'''), 120.4 (C-3a), 120.7 (C-9a), 122.7 (C-8), 125.3; 125.4 (C-9), 129.0 (C-3''', 5'''), 129.0 (C-2'', 6''), 129.4 (C-3''', 5'''), 130.5 (C-7), 135.2; 135.3 (C-1''), 137.9; 138.1 (C-9b), 140.7 (C-4''), 140.5; 140.7 (C-5'), 141.6; 141.8 (C-1'''), 150.1 (C-5a). ESI-HRMS: *m/z* [M+H]⁺ calcd for (C₂₆H₂₃N₂O₂S)⁺: 443.1207; found: 443.1211.

4.5. Synthesis of compound 13 (general procedure)

Compound **3** (1 mmol) was dissolved in anhydrous CHCl₃ (20 mL) and boiled under reflux for 24 h. The solvent was then removed under reduced pressure. The resulting residue was purified by silica gel column chromatography (EP/AcOEt, 8:2) to give compound **13**.

4.5.1. 2-Methyl-2H-thieno[3,2-c]chromene-4(3H)-thione (13)

Orange solid, yield 75%, mp 160 °C (EP/AcOEt, 8:2). ¹H NMR (300 MHz, CDCl₃): δ_H 1.45 (s, 3H, CH₃), 2.97 (dd, 1H, J = 16.5 Hz, J = 5.4 Hz, H-3a), 3.42 (dd, 1H, J = 16.5 Hz, J = 8.7 Hz, H-3b), 4.09 (m, 1H, H-2), 7.15–7.31 (m, 3H, H-6, 8, 9), 7.43 (m, 1H, H-7). ¹³C NMR (75 MHz, CDCl₃): δ_C 23.0 (CH₃), 41.4 (C-3), 45.7 (C-2), 116.7 (C-3a), 116.9 (C-6), 119.3 (C-9a), 124.2 (C-8), 125.8 (C-9), 131.7 (C-7), 157.4 (C-5a), 160.1 (C-9b), 193.2 (C-4). ES-MS *m/z* 235 [M+H]⁺.

References

- [1] D.L. Hill, *Cancer Chemother. Pharmacol.* **4** (1980) 215.
- [2] J.A. Nelson, L.M. Rose, L. Benette, *Cancer Res.* **37** (1977) 182.

- [3] K. Tsukamoto, M. Suno, K. Igarashi, Y. Kozai, Y. Sugino, *Cancer Res.* 35 (1975) 2631.
- [4] H.N. Dogan, A. Duran, S. Rollas, G. Sener, M.K. Uysal, D. Gulen, *Bioorg. Med. Chem.* 10 (2002) 2893.
- [5] N. Solak, S. Rollas, *Arkivoc* xii (2006) 181.
- [6] H.N. Hafez, M.I. Hegab, I.S.A. -Frag, A.B.A. El-Gazzar, *Bioorg. Med. Chem. Lett.* 18 (2008) 4538.
- [7] A. Foroumadi, S. Pournourmohammadi, F. Soltani, M. Asgharian-Razae, S. Dabiri, A. Kharazmi, A. Shafiee, *Bioorg. Med. Chem. Lett.* 15 (2005) 1983.
- [8] J. Chou, S. Lai, S. Pan, G. Jow, J. Chern, J. Guh, *Biochem. Pharm.* 66 (2003) 115.
- [9] F. Vergne, P. Bernardelli, E. Lorthiois, N. Pham, E. Proust, C. Oliveira, A. Mafroud, P. Ducrot, R. Wrigglesworth, F. Berlioz-Seux, F. Coleon, E. Chevalier, F. Moreau, M. Idrissi, A. Tertre, A. Descours, P. Berna, M. Li, *Bioorg. Med. Chem. Lett.* 14 (2004) 4614.
- [10] A.R. Jalilian, S. Sattari, M. Bineshmavasti, A. Shafiee, M. Danesh Talab, *Arch. Pharm. (Weinheim)* 333 (2000) 347.
- [11] M.A. Hosny, T.H. El Sayed, E.A. El Sawi, *Eur. J. Chem.* 9 (2012) 1276.
- [12] A. Shafiee, M. Mohamadpour, F. Abtahi, A. Khoyi, *J. Pharm. Sci.* 70 (1981) 510.
- [13] D. Guo, Z. Wang, Z. Fan, H. Zhao, W. Zhang, J. Cheng, J. Yang, Q. Wu, Y. Zhang, Q. Fan, *Chin. J. Chem.* 30 (2012) 2522.
- [14] E.W. Thomas, E.E. Nishizawa, D.C. Zimmermann, D.J. Williams, *J. Med. Chem.* 28 (1985) 442.
- [15] I. Manolov, C.M. -Moessmer, N. Danchev, *Eur. J. Med. Chem.* 41 (2006) 882.
- [16] J. Wu, X. Wang, Y. Yi, K. Lee, *Bioorg. Med. Chem. Lett.* 13 (2003) 1813.
- [17] A. Padwa, B.M. Trost, *FleminF I*. (Eds.), *Comprehensive Organic Chemistry*, Vol. 4, Pergamon, Oxford, UK, 1991, p. 1069.
- [18] H. Jiang, J. Zhao, X. Han, S. Zhu, *Tetrahedron* 62 (2006) 11008.
- [19] R. Huisgen, J. Sauer, M. Seidl, *Chem. Ber.* 94 (1961) 2503.
- [20] R. Huisgen, *Angew. Chem. Int. Ed. Engl.* 2 (1963) 565.
- [21] Y. Lin, S.R. Petty, F.M. Lowell, N.A. Perkinson, S.A. Lang, *J. Heterocycl. Chem.* 17 (1980) 1077.
- [22] K.C. Majumdar, M. Ghosh, *Tetrahedron* 58 (2002) 10047.
- [23] H.M. Hassaneen, A.A. Fares, N.M. Abunada, O.A. Miqdad, *Asian. J. Chem.* 24 (2012) 330.
- [24] E.V. Budarina, N.N. Labeish, V.K. Bel'skii, V.A. Galishev, *Russ. J. Org. Chem.* 41 (2005) 758.
- [25] A.A. Caleb, D. Ballo, B. Rachid, H. Amina, B. Mostapha, Z. Abdelfettah, A. El, E. Rajae, El Mokhtar, *Arkivoc* ii (2011) 217.
- [26] M.I. Hegab, A.S. Girgis, I.S.A. -Frag, *J. Heterocycl. Chem.* 43 (2006) 1237.
- [27] H. Kwart, E.R. Evans, *J. Org. Chem.* 31 (1966) 413.
- [28] K.C. Majumdar, A. Biswas, *Monatsh Chem.* 135 (2004) 1001.